Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.
News and Events
Recent Releases03/30/2015 - 4:00pm03/30/2015 - 11:00am
Researchers have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.03/26/2015 - 11:45am03/20/2015 - 10:45am
The University of Michigan Comprehensive Cancer Center received a $1.65 million gift from the Hirair and Anna Hovnanian Foundation to fund adrenal cancer research.03/17/2015 - 8:15pm
In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.